Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL5300 is an experimental small molecule belonging to the thienothiazine class of organic compounds. Its chemical formula is C11H12N2O5S4 and it has a molecular weight of approximately 380.48 g/mol. The compound acts as an inhibitor of carbonic anhydrase 2 (CA-II), a zinc metalloenzyme involved in the reversible hydration of carbon dioxide and regulation of fluid secretion in various tissues. As a carbonic anhydrase inhibitor, AL5300 may have potential applications in diseases where modulation of CA-II activity is beneficial; however, there are currently no approved indications or active clinical trials for this compound[1][2][5]. It remains at the experimental stage with no evidence of progression beyond preclinical or early research phases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AL5300.